GlassScriptPhysician profile
Daniel Frederick Boxwell
NPI 1518181148
$7,225.96
in general payments reported to CMS, 2019-2025
21 companies · $4,484 in 2025
The $4,484 reported for 2025 was more than what 96% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.02 · 2021: $38.67 · 2022: $107 · 2023: $189 · 2024: $2,332 · 2025: $4,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,418 · Food and Beverage: $2,587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,418.25 |
| Food and Beverage | $2,587.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $4,184.96 | 2024-2025 | Scopis Ent, Xpress Loprofile, Shaver System |
| Aerin Medical INC. | $1,717.73 | 2023-2025 | |
| Glaxosmithkline, LLC. | $312.32 | 2025 | Nucala |
| Regeneron Healthcare Solutions, INC. | $155.50 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $140.21 | 2024-2025 | Voquezna |
| Acclarent, INC | $130.14 | 2019-2023 | Trudi Nav Cable, Acclarent Aera, Relieva Spinplus |
| Neurent Medical Limited | $122.50 | 2022-2023 | Neuromark Radiofrequency Console, Neuromark Device |
| Actelion Pharmaceuticals US, INC. | $69.86 | 2024 | Opsumit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.97 | 2024 | Ofev |
| Genzyme Corporation | $61.59 | 2024-2025 | |
| Intersect Ent, INC. | $38.67 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $34.77 | 2025 | Tezspire |
| Advanced Bionics, LLC | $25.53 | 2022 | |
| Lundbeck LLC | $25.44 | 2025 | Vyepti |
| Amgen INC. | $23.36 | 2024 | Tezspire |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $21.31 | 2025 | Purified Cortrophin Gel |
| Insmed, INC. | $20.78 | 2025 | Arikayce |
| Xoran Technologies LLC | $20.00 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.47 | 2025 | Glassia |
| United Therapeutics Corporation | $19.39 | 2024 | Tyvaso |
| Pfizer INC. | $16.46 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Boxwell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.